CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 138 filers reported holding CLOVIS ONCOLOGY INC in Q1 2014. The put-call ratio across all filers is 0.69 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $1,645,000 | -33.6% | 1,382,968 | +0.4% | 0.00% | – |
Q2 2022 | $2,479,000 | -41.5% | 1,377,710 | -34.3% | 0.00% | -100.0% |
Q1 2022 | $4,235,000 | -29.4% | 2,096,698 | -5.2% | 0.00% | 0.0% |
Q4 2021 | $5,996,000 | -33.5% | 2,212,612 | +9.5% | 0.00% | 0.0% |
Q3 2021 | $9,011,000 | -15.9% | 2,020,571 | +9.4% | 0.00% | 0.0% |
Q2 2021 | $10,711,000 | -8.1% | 1,846,733 | +11.2% | 0.00% | -50.0% |
Q1 2021 | $11,655,000 | +79.8% | 1,660,342 | +22.9% | 0.00% | +100.0% |
Q4 2020 | $6,484,000 | -16.5% | 1,350,865 | +1.4% | 0.00% | -50.0% |
Q3 2020 | $7,763,000 | -6.9% | 1,331,618 | +7.7% | 0.00% | 0.0% |
Q2 2020 | $8,341,000 | +43.2% | 1,235,845 | +35.0% | 0.00% | 0.0% |
Q1 2020 | $5,823,000 | -61.1% | 915,710 | -36.2% | 0.00% | 0.0% |
Q4 2019 | $14,960,000 | +431.2% | 1,435,164 | +100.3% | 0.00% | +100.0% |
Q3 2019 | $2,816,000 | -72.7% | 716,664 | +3.4% | 0.00% | -50.0% |
Q2 2019 | $10,306,000 | -32.9% | 693,100 | +12.0% | 0.00% | -50.0% |
Q1 2019 | $15,363,000 | -25.2% | 619,011 | -45.9% | 0.00% | +33.3% |
Q4 2018 | $20,546,000 | +31.3% | 1,144,008 | +114.8% | 0.00% | -25.0% |
Q3 2018 | $15,643,000 | -32.8% | 532,635 | +4.0% | 0.00% | -42.9% |
Q2 2018 | $23,278,000 | -1.2% | 511,954 | +14.7% | 0.01% | -12.5% |
Q1 2018 | $23,569,000 | -20.6% | 446,397 | +2.3% | 0.01% | -20.0% |
Q4 2017 | $29,683,000 | -17.2% | 436,518 | +0.3% | 0.01% | -23.1% |
Q3 2017 | $35,869,000 | -10.1% | 435,312 | +2.1% | 0.01% | -18.8% |
Q2 2017 | $39,909,000 | +61.2% | 426,247 | +9.6% | 0.02% | +60.0% |
Q1 2017 | $24,758,000 | +91.9% | 388,857 | +33.9% | 0.01% | +66.7% |
Q4 2016 | $12,901,000 | +33.8% | 290,450 | +8.6% | 0.01% | +20.0% |
Q3 2016 | $9,643,000 | +209.7% | 267,491 | +17.8% | 0.01% | +150.0% |
Q2 2016 | $3,114,000 | -25.3% | 227,024 | +4.6% | 0.00% | 0.0% |
Q1 2016 | $4,167,000 | -44.5% | 217,062 | +1.3% | 0.00% | -50.0% |
Q4 2015 | $7,502,000 | -63.0% | 214,350 | -2.9% | 0.00% | -66.7% |
Q3 2015 | $20,297,000 | +21.6% | 220,716 | +16.2% | 0.01% | +20.0% |
Q2 2015 | $16,688,000 | +22.6% | 189,899 | +3.6% | 0.01% | +25.0% |
Q1 2015 | $13,610,000 | +39.9% | 183,350 | +5.6% | 0.01% | +33.3% |
Q4 2014 | $9,727,000 | +28.0% | 173,699 | +3.7% | 0.01% | +20.0% |
Q3 2014 | $7,600,000 | +12.6% | 167,554 | +2.8% | 0.01% | +25.0% |
Q2 2014 | $6,748,000 | -38.0% | 162,975 | +3.7% | 0.00% | -42.9% |
Q1 2014 | $10,889,000 | +19.7% | 157,209 | +4.1% | 0.01% | +16.7% |
Q4 2013 | $9,099,000 | +54.0% | 150,985 | +55.3% | 0.01% | +20.0% |
Q3 2013 | $5,909,000 | +12.0% | 97,212 | +23.4% | 0.01% | 0.0% |
Q2 2013 | $5,275,000 | – | 78,758 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 814,833 | $45,630,648,000 | 43.63% |
EcoR1 Capital, LLC | 384,348 | $21,523,000 | 10.89% |
Palo Alto Investors LP | 2,102,857 | $117,760,000 | 6.91% |
NEA Management Company, LLC | 2,279,781 | $127,668,000 | 6.19% |
Redmile Group, LLC | 721,632 | $40,411,000 | 4.40% |
Opaleye Management Inc. | 140,000 | $7,840,000 | 3.96% |
CLIFTON PARK CAPITAL MANAGEMENT, LLC | 790,555 | $44,271,000 | 2.63% |
SUFFOLK CAPITAL MANAGEMENT LLC | 339,327 | $19,002,000 | 2.31% |
PFM Health Sciences, LP | 1,725,126 | $96,607,000 | 2.26% |
HARBOURVEST PARTNERS LLC | 51,037 | $2,858,000 | 1.50% |